Events


AMP Europe 2018

Watch Dr. Atil Bisgil from Cukurova University, Turkey talk about expanding to microbiome research with the GeneReader NGS System. He discusses the pressures faced in a laboratory focused on next generation sequencing and research, looking toward the future of high-throughput NGS testing and expanding to microbiome research with the GeneReader.  


EHA 2018

Stop by the QIAGEN booth #1160 at the 23rd EHA Congress from June 14-17, 2018 at Stockholm, where we will be featuring our latest Sample to Insight solutions, from trusted molecular detection to clinical decision support.


2018 ASCO Annual Meeting

We’re excited to attend the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 in Chicago. Learn more.













QIAGEN’s GeneReader NGS System gains further validation in oncology research applications with new independent performance review data

Studies presented at AMP Global conference in Berlin reaffirm powerful analytical performance and ease of use for the world’s first complete Sample to Insight NGS solution Hilden, Germany, April 3, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced further validation of the GeneReader NGS System with the publication of five new… Read article →


QIAGEN at AMP Global 2017

The inaugural AMP Global Congress on Molecular Pathology, hosted by the Association for Medical Pathologists (AMP), is the event of the year for molecular pathology, diagnostic technologies and research and clinical applications. AMP Global 2017 is the perfect event for QIAGEN to remind and educate the market about our broad menu of Sample to Insight… Read article →


QIAGEN at AMP 2016

Join us at AMP for solutions, from trusted molecular detection to clinical decision support The AMP 2016 Annual Meeting is just around the corner, and we’re excited to see you there at the Convention Center in Charlotte, NC, Nov 10—12! Stop by our booth! Come to booth #1119 to explore our products and speak with our… Read article →


QIAGEN partners to develop predictive tests in oncology

Yesterday, we announced that QIAGEN was entering into a licensing and co-development agreement with Therawis Diagnostics GmbH to develop and commercialize predictive assays in oncology. An initial project will be to develop and market PITX2 as a marker to predict effectiveness of anthracycline treatment in triple negative and other high-risk breast cancer patients. See the full press release… Read article →